Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases
November 03 2021 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that C. Russell Trenary,
President and Chief Executive Officer of Outlook Therapeutics, will
present at the Eyecelerator@AAO 2021 Conference Retina Showcases
being held in New Orleans, Louisiana.
Details for the presentation are as follows:
Company Presentation: Retina
ShowcasesPresenter: C. Russell Trenary III - President and
Chief Executive OfficerDate and Time: Thursday, November 11, 2021,
1:10 PM – 1:15 PM EST
Eyecelerator is a partnership between the
American Academy of Ophthalmology (AAO) and the American Society of
Cataract and Refractive Surgery (ASCRS) that aims to connect
entrepreneurs, investors, companies and physicians to advance
ophthalmic innovation through live conferences, virtual programming
and a next-generation networking platform. For more information and
to register for this event, please visit
Eyecelerator@AAOAbout Outlook Therapeutics,
Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved,
Outlook Therapeutics expects to commercialize it as the first and
only FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United Kingdom,
Europe, Japan and other markets. Outlook Therapeutics expects to
submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA
under the PHSA 351(a) regulatory pathway. For more information,
please visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice PresidentLaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries:Jenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jul 2023 to Jul 2024